Citadel Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-47,821
| Closed | -$17K | – | 8377 |
|
|
2016
Q3 | $17K | Sell |
47,821
-196,413
| -80% | -$69.8K | ﹤0.01% | 7103 |
|
|
2016
Q2 | $114K | Buy |
+244,234
| New | +$114K | ﹤0.01% | 6137 |
|
|
2016
Q1 | – | Sell |
-17,229
| Closed | -$25K | – | 9203 |
|
|
2015
Q4 | $25K | Sell |
17,229
-46,174
| -73% | -$67K | ﹤0.01% | 7797 |
|
|
2015
Q3 | $100K | Sell |
63,403
-16,760
| -21% | -$26.4K | ﹤0.01% | 6962 |
|
|
2015
Q2 | $136K | Sell |
80,163
-75,753
| -49% | -$129K | ﹤0.01% | 6759 |
|
|
2015
Q1 | $217K | Buy |
155,916
+139,663
| +859% | +$194K | ﹤0.01% | 6086 |
|
|
2014
Q4 | $25K | Buy |
16,253
+15,043
| +1,243% | +$23.1K | ﹤0.01% | 7662 |
|
|
2014
Q3 | $2K | Sell |
1,210
-41,250
| -97% | -$68.2K | ﹤0.01% | 8028 |
|
|
2014
Q2 | $130K | Sell |
42,460
-71,145
| -63% | -$218K | ﹤0.01% | 6004 |
|
|
2014
Q1 | $284K | Buy |
113,605
+91,270
| +409% | +$228K | ﹤0.01% | 5084 |
|
|
2013
Q4 | $111K | Buy |
22,335
+3,079
| +16% | +$15.3K | ﹤0.01% | 5535 |
|
|
2013
Q3 | $44K | Buy |
19,256
+8,771
| +84% | +$20K | ﹤0.01% | 5870 |
|
|
2013
Q2 | $23K | Buy |
+10,485
| New | +$23K | ﹤0.01% | 6024 |
|
Citadel Advisors's RXII Position: Q4 2016 in Review
Citadel Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 47,821 shares — an estimated $17K sold.
Citadel Advisors first reported a position in RXII in Q2 2013 and held it in 13 quarters. The position peaked at $284K in Q1 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Citadel Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Citadel Advisors sold 47,821 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $17K.
- Citadel Advisors first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 13 quarters.
- Citadel Advisors's GALENA BIOPHARMA INC COM position peaked at $284K in Q1 2014.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.